Product Images Arnuity Ellipta

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 23 images provide visual information about the product associated with Arnuity Ellipta NDC 0173-0888 by Glaxosmithkline Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

fluticasone furoate chemical structure - arnuityellipta spl graphic 01

fluticasone furoate chemical structure - arnuityellipta spl graphic 01

Figure 1. Impact of Intrinsic Factors on the Pharmacokinetics (PK) of Fluticasone Furoate (FF) - arnuityellipta spl graphic 02

Figure 1. Impact of Intrinsic Factors on the Pharmacokinetics (PK) of Fluticasone Furoate (FF) - arnuityellipta spl graphic 02

Figure 2. Impact of Coadministered Ketoconazolea on the Pharmacokinetics (PK) of Fluticasone Furoate - arnuityellipta spl graphic 03

Figure 2. Impact of Coadministered Ketoconazolea on the Pharmacokinetics (PK) of Fluticasone Furoate - arnuityellipta spl graphic 03

This text seems to be a table displaying the impact of extrinsic factors on Fluticasone Furoate PK (pharmacokinetics) with respect to an interacting drug. The table lists fold changes and 90% confidence intervals of Fluticasone Furoate's area under the curve (AuC) and maximum concentration (Cmax) in response to different dosages of the interacting drug. The only drug mentioned here is "Ketoconazole" which seems to reduce Fluticasone Furoate's AuC and Cmax. The table recommends caution while prescribing Fluticasone Furoate in conjunction with Ketoconazole.*

Figure 3. Dose-Ranging Trials - arnuityellipta spl graphic 04

Figure 3. Dose-Ranging Trials - arnuityellipta spl graphic 04

Figure 4. Mean Change from Baseline in Individual Serial FEV1 (mL) Assessments after 12 Weeks of Treatment – Trial 2 - arnuityellipta spl graphic 05

Figure 4. Mean Change from Baseline in Individual Serial FEV1 (mL) Assessments after 12 Weeks of Treatment – Trial 2 - arnuityellipta spl graphic 05

This is a table displaying LS Mean Change from Baseline (measured in mL) and Planned Time since Dose (measured in hours) for ARNUITY ELLIPTA 100 mcg once daily and Placebo. The values for LS Mean Change from Baseline are 70, 500, 0, 300, 20, and 100. The values for Planned Time since Dose are not specified.*

Figure 5. Mean Change from Baseline in Trough FEV1 (mL) over Time – Trial 3 - arnuityellipta spl graphic 06

Figure 5. Mean Change from Baseline in Trough FEV1 (mL) over Time – Trial 3 - arnuityellipta spl graphic 06

Figure 6. Mean Change from Baseline in Individual Serial FEV1 (mL) Assessments after 24 Weeks of Treatment – Trial 4 - arnuityellipta spl graphic 07

Figure 6. Mean Change from Baseline in Individual Serial FEV1 (mL) Assessments after 24 Weeks of Treatment – Trial 4 - arnuityellipta spl graphic 07

Parts figure - arnuityellipta spl graphic 08

Parts figure - arnuityellipta spl graphic 08

PIL Figure A - arnuityellipta spl graphic 09

PIL Figure A - arnuityellipta spl graphic 09

PIL Figure B - arnuityellipta spl graphic 10

PIL Figure B - arnuityellipta spl graphic 10

PIL Figure C - arnuityellipta spl graphic 11

PIL Figure C - arnuityellipta spl graphic 11

PIL Figure D - arnuityellipta spl graphic 12

PIL Figure D - arnuityellipta spl graphic 12

PIL Figure E - arnuityellipta spl graphic 13

PIL Figure E - arnuityellipta spl graphic 13

PIL Figure F - arnuityellipta spl graphic 14

PIL Figure F - arnuityellipta spl graphic 14

PIL Figure G - arnuityellipta spl graphic 15

PIL Figure G - arnuityellipta spl graphic 15

PIL Figure H - arnuityellipta spl graphic 16

PIL Figure H - arnuityellipta spl graphic 16

PIL Figure I - arnuityellipta spl graphic 17

PIL Figure I - arnuityellipta spl graphic 17

PIL Figure J - arnuityellipta spl graphic 18

PIL Figure J - arnuityellipta spl graphic 18

PIL Figure K - arnuityellipta spl graphic 19

PIL Figure K - arnuityellipta spl graphic 19

PIL Figure L - arnuityellipta spl graphic 20

PIL Figure L - arnuityellipta spl graphic 20

Arnuity Ellipta 100mcg 30 count carton - arnuityellipta spl graphic 21

Arnuity Ellipta 100mcg 30 count carton - arnuityellipta spl graphic 21

This is a medication called Arnuity Ellipta, which is a powder that is inhaled orally for treating breathing problems. Each blister pack contains 50mcg of the active ingredient, Fluticasone Furoate, along with lactose monohydrate. The National Drug Code (NDC) for this medication is 0173-0888-10.*

Arnuity Ellipta 200mcg 30 count carton - arnuityellipta spl graphic 22

Arnuity Ellipta 200mcg 30 count carton - arnuityellipta spl graphic 22

The text describes a medication called ANNUITY ELLIPTA, with the NDC code of 0173-0874-10. It is a prescription medication that contains fluticasone furoate inhalation powder and lactose monohydrate, which is used for oral inhalation only. Each blister pack contains 100 micrograms of the medication.*

arnuityellipta spl graphic 23

arnuityellipta spl graphic 23

This text is a label for medication. The medication is called "Fluticasone Furoate Inhalation Powder" and comes in a package with the trade name "N UITY ELLIPTA". It is intended for oral inhalation only and contains 200 mcg of fluticasone furoate and lactose monohydrate per blister. The package is only available with a prescription (Rx Only).*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.